The Effect of Different Anesthetic Techniques on Proliferation, Apoptosis, and Gene Expression in Colon Cancer Cells: A Pilot In Vitro Study.
anesthesia
cell culture
colon cancer
lidocaine
propofol
tumor suppressor gene
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
14 Jan 2023
14 Jan 2023
Historique:
received:
06
12
2022
revised:
07
01
2023
accepted:
10
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Colorectal cancer is highly common and causes high mortality rates. Treatment for colorectal cancer is multidisciplinary, but in most cases the main option remains surgery. Intriguingly, in recent years, a number of studies have shown that a patient's postoperative outcome may be influenced by certain anesthetic drugs. Our main objective was to compare the effect of propofol-total intravenous anesthesia (TIVA) with sevoflurane anesthesia and to investigate the potential role of intravenous lidocaine on colon cancer cell functions. We tested the effects of serum from colorectal cancer patients undergoing TIVA vs. sevoflurane anesthesia with or without lidocaine on HCT 116 cell lines; on proliferation, apoptosis, migration, and cell cycles; and on cancer-related gene expressions. 60 patients who were scheduled for colorectal cancer surgery were randomized into four different groups (two groups with TIVA and two groups with sevoflurane anesthesia with or without intravenous lidocaine). Blood samples were collected at the start and at the end of surgery. HCT 116 cells were exposed to the patients' serum. 15 patients were included in each of the study groups. We did not find any significant difference on cell viability or apoptosis between the study groups. However, there was an increased apoptosis in propofol groups, but this result was not statistically significant. A significant increase in the expression profile of the In our study, serum from patients receiving different anesthetic techniques did not significantly influence the apoptosis, migration, and cell cycle of HCT-116 colorectal carcinoma cells. Viability was also not significantly influenced by the anesthetic technique, except the sevoflurane-lidocaine group where it was increased. The gene expression of
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer is highly common and causes high mortality rates. Treatment for colorectal cancer is multidisciplinary, but in most cases the main option remains surgery. Intriguingly, in recent years, a number of studies have shown that a patient's postoperative outcome may be influenced by certain anesthetic drugs. Our main objective was to compare the effect of propofol-total intravenous anesthesia (TIVA) with sevoflurane anesthesia and to investigate the potential role of intravenous lidocaine on colon cancer cell functions. We tested the effects of serum from colorectal cancer patients undergoing TIVA vs. sevoflurane anesthesia with or without lidocaine on HCT 116 cell lines; on proliferation, apoptosis, migration, and cell cycles; and on cancer-related gene expressions.
METHODS
METHODS
60 patients who were scheduled for colorectal cancer surgery were randomized into four different groups (two groups with TIVA and two groups with sevoflurane anesthesia with or without intravenous lidocaine). Blood samples were collected at the start and at the end of surgery. HCT 116 cells were exposed to the patients' serum.
RESULTS
RESULTS
15 patients were included in each of the study groups. We did not find any significant difference on cell viability or apoptosis between the study groups. However, there was an increased apoptosis in propofol groups, but this result was not statistically significant. A significant increase in the expression profile of the
CONCLUSIONS
CONCLUSIONS
In our study, serum from patients receiving different anesthetic techniques did not significantly influence the apoptosis, migration, and cell cycle of HCT-116 colorectal carcinoma cells. Viability was also not significantly influenced by the anesthetic technique, except the sevoflurane-lidocaine group where it was increased. The gene expression of
Identifiants
pubmed: 36661535
pii: cimb45010049
doi: 10.3390/cimb45010049
pmc: PMC9857142
doi:
Types de publication
Journal Article
Langues
eng
Pagination
738-751Subventions
Organisme : Iuliu Hațieganu University of Medicine and Pharmacy
ID : Doctoral research project no.1529/3/18 January 2019
Références
J BUON. 2019 Jan-Feb;24(1):106-115
pubmed: 30941958
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Lancet. 2019 Nov 16;394(10211):1807-1815
pubmed: 31645288
Front Oncol. 2022 Mar 28;12:837974
pubmed: 35419287
J Pharmacol Exp Ther. 1999 Feb;288(2):660-4
pubmed: 9918572
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Br J Anaesth. 2009 Nov;103(5):685-90
pubmed: 19776028
BMC Anesthesiol. 2019 Dec 18;19(1):233
pubmed: 31852445
Med Sci Monit. 2018 Sep 03;24:6119-6128
pubmed: 30174326
Perioper Med (Lond). 2019 Feb 26;8:1
pubmed: 30858969
Eur J Pharmacol. 2019 May 5;850:43-52
pubmed: 30685432
Pathol Res Pract. 2018 Dec;214(12):1974-1979
pubmed: 30262429
Anaesthesia. 2021 Feb;76(2):238-250
pubmed: 33141959
Front Med (Lausanne). 2022 Feb 18;9:799355
pubmed: 35252243
Br J Anaesth. 2014 Jul;113 Suppl 1:i63-7
pubmed: 25009197
Front Med (Lausanne). 2017 Dec 20;4:235
pubmed: 29326939
Anesthesiology. 2016 Jan;124(1):69-79
pubmed: 26556730
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Anticancer Res. 2017 Apr;37(4):1941-1945
pubmed: 28373464
Gastroenterol Rep (Oxf). 2016 Feb;4(1):30-4
pubmed: 25688100
Cold Spring Harb Perspect Med. 2016 May 02;6(5):
pubmed: 27141080
BMC Cancer. 2018 Jun 19;18(1):666
pubmed: 29914426
Br J Anaesth. 2018 Oct;121(4):962-968
pubmed: 30236259
Anaesthesia. 2016 Feb;71(2):147-54
pubmed: 26669824
BMC Cancer. 2021 Nov 10;21(1):1193
pubmed: 34758772
Front Med (Lausanne). 2021 Aug 11;8:658926
pubmed: 34458282
Int J Physiol Pathophysiol Pharmacol. 2019 Jun 25;11(3):83-94
pubmed: 31333811
Reg Anesth Pain Med. 2010 Nov-Dec;35(6):490-5
pubmed: 20975461
Trials. 2022 Mar 18;23(1):219
pubmed: 35303929
Arch Med Res. 2020 Apr;51(3):233-244
pubmed: 32139108
J Transl Med. 2018 Jan 18;16(1):8
pubmed: 29347949
Front Oncol. 2021 Jun 24;11:669746
pubmed: 34249706
Anesthesiology. 2017 May;126(5):868-881
pubmed: 28121635
Cancer Cell Int. 2021 Dec 24;21(1):703
pubmed: 34952583
Rev Esp Anestesiol Reanim. 2015 Dec;62(10):570-5
pubmed: 26026503
Eur J Surg Oncol. 2016 Sep;42(9):1286-95
pubmed: 27265039
J Clin Med. 2021 Feb 11;10(4):
pubmed: 33670434